WallStSmart
CRBP

Corbus Pharmaceuticals Holding

NASDAQ: CRBP · HEALTHCARE · BIOTECHNOLOGY

$11.43
-5.62% today

Updated 2026-06-05

Market cap
$140.07M
P/E ratio
P/S ratio
169.88x
EPS (TTM)
$-5.74
Dividend yield
52W range
$7 – $21
Volume
0.5M

Corbus Pharmaceuticals Holding (CRBP) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20122013201420152016201720182019202020212022202320242025
Operating cash flow$-769.00$-366715.00$-2.36M$-4.65M$-13.57M$-27.80M$-30.07M$-45.72M$-99.69M$-48.18M$-37.54M$-36.10M$-41.79M$-64.49M
Capital expenditures$0.00$0.00$64448.00$114037.00$353032.00$707429.00$2.30M$2.74M$484487.00$54172.00$13449.00$3.00$0.00$7000.00
Depreciation
Stock-based comp$26.00$6141.00$193120.00$1.15M$3.16M$5.69M$7.61M$11.98M$12.46M$9.48M$5.72M$3.47M$6.14M$6.29M
Free cash flow$-769.00$-366715.00$-2.43M$-4.76M$-13.92M$-28.50M$-32.37M$-48.46M$-100.17M$-48.24M$-37.56M$-36.10M$-41.79M$-64.50M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$0.00$0.00
Share repurchases
Debt repayment
Net change in cash$5.96M$6.08M$2.82M$47.50M$-20.95M$-10.00M$54.70M

Frequently asked questions

How much free cash flow does CRBP generate?

CRBP produced $-64.50M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CRBP's balance sheet healthy?

CRBP holds $28.49M in cash and equivalents against — in long-term debt, on $147.50M of shareholder equity. That debt is best read against the cash flow the business throws off each year.